Download Files:
JBI-589
$500 – $5,800
Products Details
Product Description
– JBI-589 is a non-covalent PAD4 isoform-selective inhibitor. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors[1].
Web ID
– HY-153450
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-programmed cell death
Molecular Formula
– C29H28FN5O
References
– [1]Deng H, et al. A Novel Selective Inhibitor JBI-589 Targets PAD4-Mediated Neutrophil Migration to Suppress Tumor Progression. Cancer Res. 2022 Oct 4;82(19):3561-3572.|[2]Gajendran C, et al. Alleviation of arthritis through prevention of neutrophil extracellular traps by an orally available inhibitor of protein arginine deiminase 4. Sci Rep. 2023 Feb 23;13(1):3189.
CAS Number
– 2308504-22-3
Molecular Weight
– 481.56
Compound Purity
– 98.34
SMILES
– CC(N1C(C=C(C=C1)C(N2C[C@@H](CCC2)N)=O)=N3)=C3C4=CC5=CC=CC=C5N4CC6=CC=C(C=C6)F
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 125 mg/mL (ultrasonic)
Target
– Protein Arginine Deiminase
Pathway
– Epigenetics
Product type
– Reference compound
Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.
